Farhad Ravandi-Kashani
M.D. Anderson Cancer Center
7
7
1
N/A
0
17
Research Impact
N/A
Research impact score
0
Total publications
0
Published trial results
0
Total citations
Drug Portfolio
+15 more interventions
Analytics
Trial Phases
Trial Status
Role Distribution
Activity Timeline
Clinical Trials (7)
Research Network
Collaboration Network
Research Areas & Affiliations
Therapeutic Areas
Affiliations
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
Farhad Ravandi-Kashani, MD
M.D. Anderson Cancer Center
Shared therapeutic areas:
Worked with same sponsors:
Elias Jabbour
M.D. Anderson Cancer Center
Shared therapeutic areas:
Worked with same sponsors:
Courtney DiNardo, MD
M.D. Anderson Cancer Center
Shared therapeutic areas:
Worked with same sponsors:
Jae Park, MD
Memorial Sloan Kettering Cancer Center
Shared therapeutic areas:
Worked with same sponsors:
Jorge Cortes, MD
M.D. Anderson Cancer Center
Shared therapeutic areas:
Worked with same sponsors:
Qifa Liu
Nanfang Hospital, Southern Medical University
Shared therapeutic areas:
Elias Jabbour, MD
M.D. Anderson Cancer Center
Shared therapeutic areas:
Worked with same sponsors:
Beata Holkova, MD
Massey Cancer Center
Shared therapeutic areas:
Worked with same sponsors:
Areej El-Jawahri, MD
Massachusetts General Hospital
Shared therapeutic areas:
Worked with same sponsors:
Yifan Zhai, MD, PhD
Ascentage Pharma Group Inc.
Shared therapeutic areas:
Publications (0)
No publications found for this investigator.
Clinical Trials (7)
Showing 7 of 7 trials
ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia
Ruxolitinib Phosphate and Decitabine in Treating Patients With Relapsed or Refractory or Post Myeloproliferative Acute Myeloid Leukemia
Tretinoin and Arsenic Trioxide With or Without Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
SJG-136 in Treating Patients With Relapsed or Refractory Acute Leukemia, Myelodysplastic Syndromes, Blastic Phase Chronic Myelogenous Leukemia, or Chronic Lymphocytic Leukemia
All 7 trials loaded